Parkinson’s Drug Delivered, Not Just Parkinson’s Disease Dementia Drug! $AVXL

Etiology Battle Won The first paragraph says it all. ANAVEX┬«2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the primary and secondary clinical efficacy endpoints CoA (p = 0.029) and MDS-UPDRS Part III (p = 0.024) and MDS-UPDRS Total (p = 0.038) Wherever Blarcamesine … Continue reading Parkinson’s Drug Delivered, Not Just Parkinson’s Disease Dementia Drug! $AVXL

Intense Politics of Biogen’s Aduhelm and Companies like Anavex Life Sciences and Annovis. $BIIB $AVXL $ANVS

"Phase 4" and Aduhelm Biogen's Aduhelm has been approved along the line of pratice in cancer drugs field where barely promissing drugs are allowe to go on with the caveat of phase 4 - post approval verification that the efficay is there when patient numbers are large enough. No wonder that Big Pharma loves this … Continue reading Intense Politics of Biogen’s Aduhelm and Companies like Anavex Life Sciences and Annovis. $BIIB $AVXL $ANVS

Rett Syndrome Phase 2 (RS-001) Which was Really Phase 1 Which Turned Almost into Phase 3 $AVXL

To start talking about the 15 person dosed cohort in RS-001 Phase 2 one has to get on the subject of the dose right away. At 5mg/daily, it seems that $AVXL thought it was dispencing poison to the girls, when the maximum dose is 50mg/daily. By all accounts, that is only 1/10 of the maximum … Continue reading Rett Syndrome Phase 2 (RS-001) Which was Really Phase 1 Which Turned Almost into Phase 3 $AVXL

Aduhelm (Aducanumab) Value vs. Its Truly Restricted Market, and The Same for Blarcamesine $BIIB $AVXL

Biogen surge of $15bln in market capitalization due to Aduhelm approval does match the restricted market the drug faces. I am taking off where Lane Simonian left without giving any numbers in its latest SeekingAlpha article, link: https://seekingalpha.com/article/4435705-post-biogen-post-amyloid-world-for-alzheimers-disease . Following Bazilian study looked at the incidence of all allels of the APOE gene in Late-Onset … Continue reading Aduhelm (Aducanumab) Value vs. Its Truly Restricted Market, and The Same for Blarcamesine $BIIB $AVXL

Post On “Multi-Targeted Ligands (MTDLs) Binding the SIGMAR1 Receptor as Promising Therapeutics” $AVXL Blarcamesine Anavex3-71

The paper of the same title, link here https://www.mdpi.com/1422-0067/22/12/6359 , described number of compounds and their chemistry, among them it mentioned ANAVEX 2-73 and 3-71 as examples of the most studied drugs in the class of MTDLs drugs. It also listed number of other drugs and their targets besides SIGMAR1, touching here on the logic … Continue reading Post On “Multi-Targeted Ligands (MTDLs) Binding the SIGMAR1 Receptor as Promising Therapeutics” $AVXL Blarcamesine Anavex3-71

Two Measures of Efficacy in Alzheimer’s Trials. Blarcamesine $AVXL $SAVA $ANVS

There are two measures by which go trials of Alzheimer's/dementia. The most popular and the most expeditious is the average increase/decrease in MMSE or ADAS-Cog points of the dosed cohort vs. the placebo. The other is taking much more time and is probably more telling of the drugs potential. It is the number of dropouts … Continue reading Two Measures of Efficacy in Alzheimer’s Trials. Blarcamesine $AVXL $SAVA $ANVS

Is There More than Just Alzheimer’s, Parkinson’s and Rett Syndrome in Blarcamesine Bag of Tricks? $AVXL

See press release from Anavex Life Sciences. https://www.anavex.com/anavex-life-sciences-announces-notice-of-allowance-for-u-s-patent-application-anavex2-73-blarcamesine-for-the-treatment-of-cardiac-dysfunctions/ Heart has its own little nervous system which in part is independent from the brain. Blarcamsine as SIGMAR1 agonist does its work as far as we know primarily in the nervous cells. Yet, the SIGMAR1 receptors are expressed in different organs too. I was trying to provide … Continue reading Is There More than Just Alzheimer’s, Parkinson’s and Rett Syndrome in Blarcamesine Bag of Tricks? $AVXL